Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: N who wrote (25002)	8/30/1998 2:40:00 PM
From: Cheryl Galt	Read Replies (1) \| Respond to of 32384

Hi Nancy, I'll go along with most everything you said -- except that fan-club bit.ÿ There I have to draw a line. Please, don't be offended if I say,"Please --just don't."ÿ I'm merely campaigning for a quiet place where people can hear each other and exchange ideas without belittling each other.ÿ I'm muddling forth same as everybody else.ÿ No big deal.ÿ And my prudish style is probably irritating enough to lots of peopleÿ --- so please don't call attention to it! Anyway, from one moron to another, welcome back. Cheryl ÿ

To: N who wrote (25002)	8/31/1998 5:51:00 AM
From: Henry Niman	Respond to of 32384

Nancy, Apology accepted although I do not recall commenting directly on Asia. Recent analysis (several months ago) by H&Q suggested that Biotechs were somewhat immune from Asia because they had few products there. However, as was seen very clearly last week, investors were trying to distance themselves from risk, and Biotechs without products fall into that "risky" category in the eyes of many investors. I suspect that when money comes back into the sector, more mature companies (those with advanced products or near term profits) who have been hit hard, will be among the first to rebound sharply and of course LGND should have products at the end of this year and profits next year.